Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors

NCT05283330 is registered in ClinicalTrials.gov with Orano Med Theranostics, SAS as lead sponsor.

NCT NCT05283330
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05283330 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Open-Label, First-in-human, Dose Escalation and Expansion Study to Determine the Safety, Tolerability, Dosimetry, Pharmacokinetics, and Preliminary Efficacy of 212Pb-DOTAM-GRPR1 in Adult Participants With Recurrent or Metastatic GRPR-expressing Tumors
Lead sponsor
Orano Med Theranostics, SAS
Phase
Phase 1
Overall status
Recruiting
Start date
December 22, 2022
Completion date
May 31, 2032
Enrollment
48 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, colon cancer, glioblastoma, mcrpc (metastatic castration-resistant prostate cancer), nonsmall cell lung cancer, nsclc